Quince Therapeutics Inc. has announced its participation in the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society in the United Kingdom. During the event, Quince will provide updates on its pivotal Phase 3 NEAT clinical trial, which is focused on evaluating the neurological effects of eDSP treatment in patients with Ataxia-Telangiectasia (A-T). The trial, currently in the enrollment phase, has secured 99 participants to date. Key opinion leaders at the conference will present post hoc data analyses from Quince's prior Phase 3 ATTeST clinical trial. Topline results from the NEAT trial are expected to be reported in the first quarter of 2026, with a potential New Drug Application (NDA) submission to the FDA anticipated in the second half of 2026, contingent on positive outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.